Company Snapshot: Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer. It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
- Nov 28 2023 Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
- Nov 9 2023 Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
- Nov 6 2023 Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Nov 3 2023 Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update